Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature

Trial Profile

Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature

Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Jul 2018

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 19 Feb 2018 Planned End Date changed from 1 Jan 2024 to 1 Jul 2024.
    • 19 Feb 2018 Planned primary completion date changed from 1 Jan 2019 to 1 Apr 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top